The Efficacy of Platelet-Rich-Plasma for prevention of the knee joint cartilage degeneration after anterior cruciate ligament reconstruction

The Efficacy of Platelet-Rich-Plasma for prevention of the knee joint cartilage degeneration after anterior cruciate ligament reconstruction: a single-blind randomized trial - The Efficacy of Platelet-Rich-Plasma for prevention of the knee joint cartilage degeneration after anterior cruciate ligament reconstruction

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTb030200391

Enrollment

Registered

2021-03-02

Start date

2021-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients after anterior cruciate ligament reconstruction

Interventions

Intervention 1: Administration of specific cell processed product (PRP) Intervention 2: Dry needle (only synovial fluid collection)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 At the time of obtaining consent, the age is between 20 and 50 2 Male and female 3 Kellgren-Lawrence classification 2 or less 4 Single bundle reconstruction surgery using semitendinosus tendon as reconstruction ligament 5 First injury 6 BMI is less than 35 7 Those who have received a sufficient explanation, fully understood, and obtained free written consent. 8 In addition, those who the doctor deems appropriate

Exclusion criteria

Exclusion criteria: 1 Ligament compound injury (posterior cruciate ligament, lateral support mechanism) 2 Merge of medial collateral ligament injuries requiring repair 3 Femoro-Tibial Angle: FTA left and right difference is 10 degrees or more 4 Whole body motor disease 5 Patients with malignant neoplasms currently being treated 6 Patients with active infectious disease (including HBV, HCV, HTLV-1, HIV, syphilis) 7 Rheumatoid arthritis 8 Blood disease 9 Mental illness 10 pregnant 11 Drug addict 12 Person on dialysis 13 Those under 20 and over 50 14 Patients who cannot measure communication 15 Patients who are judged not suitable by the research doctor

Design outcomes

Primary

Measure	Time frame
T2 value of knee joint cartilage	—

Secondary

Measure	Time frame
Pain assessment (Visual Analog Scale (VAS), Knee injury and Osteoarthritis Outcome Score (KOOS)) Blood test (CBC, Biochemical examination) Blood, urine, and synovial fluid biomarkers X-ray (narrowing of joint space, osteophytes, cysts, Femorotibial angle (FTA)) MRI (cartilage thickness and volume by 3D-MRI, semi-quantitative whole organ MRI score (WORMS)) Physical examinations (swelling, warmth, tenderness, range of motion of joints, muscle strength measurement (muscle measuring device), joint stability measurement (three-dimensional accelerometer (KiRA))	—

Measure

Time frame

Pain assessment (Visual Analog Scale (VAS), Knee injury and Osteoarthritis Outcome Score (KOOS)) Blood test (CBC, Biochemical examination) Blood, urine, and synovial fluid biomarkers X-ray (narrowing of joint space, osteophytes, cysts, Femorotibial angle (FTA)) MRI (cartilage thickness and volume by 3D-MRI, semi-quantitative whole organ MRI score (WORMS)) Physical examinations (swelling, warmth, tenderness, range of motion of joints, muscle strength measurement (muscle measuring device), joint stability measurement (three-dimensional accelerometer (KiRA))

—

Countries

Japan

Contacts

Public ContactSaita Yoshitomo

Juntendo university

ysaita@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026